Compare Inovio Pharmaceuticals Inc (INO) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs PepsiCo, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while PepsiCo, Inc. trades at $125.97 (market cap $174.89B). The key difference: PepsiCo, Inc. is far larger — about 1558.9× Inovio Pharmaceuticals Inc's market cap, and PepsiCo, Inc. pays a 4.61% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and PepsiCo, Inc. for 107 Days on average.
| INO | PEP | |
|---|---|---|
Market Cap | $112.19M | $174.89B |
Volume | 3,201,278 | 23,968,864 |
Sector | Health | Consumer Staples |
52-Week High | $2.60 | $170.44 |
52-Week Low | $0.66 | $123.64 |
Typical Hold Time | 43 Days | 107 Days |
Enterprise Value | $83.51M | $215.61B |
Dividend Yield | — | 4.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
PepsiCo (PEP) trades at $128.88, up 4.24% today, with a bearish technical signal but strong fundamentals including a 16.14 P/E ratio and 51.59% ROE. Recent quarters show consistent earnings beats, with Q3 2026 EPS of $2.34 exceeding expectations. The company maintains robust cash flow, with 2025 operating cash flow of $12.09 billion, and announced a $1.48 dividend for H2-2026. News highlights price cuts on snacks like Doritos to address consumer pushback on high prices.
The outlook is mixed: analyst consensus targets $146.77 (14% upside) with a 'Hold' bias, but technicals suggest near-term pressure. Risks include competitive pricing pressures and debt levels, while opportunities lie in margin recovery and North American turnaround efforts. The stock offers value with a reasonable valuation and dividend yield, but requires monitoring of volume trends post-price adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
